Peter P Sayeski

Peter P Sayeski,

PROFESSOR

Department: MD-PHYSIOLOGY FUNCTIONAL GENOM
Business Phone: (352) 392-1816
Business Email: psayeski@ufl.edu

Teaching Profile

Courses Taught
2007-2009,2012-2019,2017-2022
GMS6406 Fundamentals of Pulmonary/Respiratory Physiology
2012-2022
GMS6410 Physiology of the Circulation of Blood
2018-2022
GMS6400C Principles of Physiology
2014,2016-2021
BMS3521 Human Physiology in Translation
2016-2022
GMS6402 Medical Respiration Physiology
2017,2019-2022
MDU4008 Aspects of the Art of Medicine
2020
MDT7090 Elective Topics
2020-2022
BMS6633 The Cv System
2016-2018,2020-2022
BMS6642 The Resp Sys Hlth
2009,2011-2022
DEN5120C Physiology
2018
GMS7980 Research for Doctoral Dissertation
2013,2015-2017,2017
GMS6051 Signal Transduction
2013-2014
BMS4905 Medical Sciences Senior Research
2012-2013
BSC3096 Human Physiology
2006-2010
GMS6491 Journal Club in Physiology
2008
HSC4970 Senior Honors Thesis
2021
GMS6470 Adv. Respiration Physiology 1
2021-2022
BMS6632 Endo and Reproduction
2022
GMS6479 Medical Gastrointestinal Physiology
2022
GMS6408 Fundamentals of Renal Physiology

Publications

2017
Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.
Gut. 66(1):145-155 [DOI] 10.1136/gutjnl-2015-309600. [PMID] 26385087.
2017
Whole-exome sequencing in evaluation of patients with venous thromboembolism.
Blood advances. 1(16):1224-1237 [DOI] 10.1182/bloodadvances.2017005249. [PMID] 29296762.
2016
Identification of 8-Hydroxyquinoline Derivatives Active Against Somatic V658F Mutant JAK1-Dependent Cells.
Archiv der Pharmazie. 349(12):925-933 [DOI] 10.1002/ardp.201600246. [PMID] 27862215.
2016
Identification of myeloproliferative neoplasm drug agents via predictive simulation modeling: assessing responsiveness with micro-environment derived cytokines.
Oncotarget. 7(24):35989-36001 [DOI] 10.18632/oncotarget.8540. [PMID] 27056884.
2015
Perturbation of Jak2-Dependent Transcriptional and Inflammatory Gene Expression in Polycythaemia Vera
British Journal of Haematology. 169(1, SI)
2014
Ectoderm Specific Deletion of Jak2 Results in Developmental and Neuronal Abnormalities
The FASEB's Journal. 28(1, S)
2014
Elevated levels of mast cells are involved in pruritus associated with polycythemia vera in JAK2V617F transgenic mice.
Journal of immunology (Baltimore, Md. : 1950). 193(2):477-84 [DOI] 10.4049/jimmunol.1301946. [PMID] 24920845.
2014
Hemodynamic regulator and mitogenic growth factor: re-visiting the age old question with ACE2 and Jak2.
Regulatory peptides. 189:v-vi [DOI] 10.1016/j.regpep.2014.03.002. [PMID] 24631470.
2014
The Jak2 small molecule inhibitor, G6, reduces the tumorigenic potential of T98G glioblastoma cells in vitro and in vivo.
PloS one. 9(8) [DOI] 10.1371/journal.pone.0105568. [PMID] 25162558.
2013
Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans.
PloS one. 8(3) [DOI] 10.1371/journal.pone.0059675. [PMID] 23544085.
2013
Identification of Jak2 Dependent Transcriptional Regulators in Cml
Experimental Hematology. 41
2012
A shift in the salt bridge interaction of residues D620 and E621 mediates the constitutive activation of Jak2-H538Q/K539L.
Molecular and cellular biochemistry. 367(1-2):125-40 [DOI] 10.1007/s11010-012-1326-7. [PMID] 22584586.
2012
A46, a benzothiophene-derived compound, suppresses Jak2-mediated pathologic cell growth.
Experimental hematology. 40(1):22-34 [DOI] 10.1016/j.exphem.2011.10.003. [PMID] 22019628.
2012
Aberrant Functions of Mast Cells Are Involved in Pruritus Associated With Polycythemia Vera
Blood. 120
2012
Angiotensin II mediates cell survival through upregulation and activation of the serum and glucocorticoid inducible kinase 1.
Cellular signalling. 24(2):435-442 [DOI] 10.1016/j.cellsig.2011.09.016. [PMID] 21963429.
2012
Identification of novel SAR properties of the Jak2 small molecule inhibitor G6: significance of the para-hydroxyl orientation.
Bioorganic & medicinal chemistry letters. 22(3):1402-7 [DOI] 10.1016/j.bmcl.2011.12.042. [PMID] 22227213.
2012
The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.
The American journal of pathology. 181(3):858-65 [DOI] 10.1016/j.ajpath.2012.05.033. [PMID] 22796437.
2011
A Structure-Function Perspective of Jak2 Mutations and Implications for Alternate Drug Design Strategies: the Road Not Taken
. 18:4659-4673
2011
A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.
Current medicinal chemistry. 18(30):4659-73 [PMID] 21864276.
2011
Cell death induced by the Jak2 inhibitor, G6, correlates with cleavage of vimentin filaments.
Biochemistry. 50(36):7774-86 [DOI] 10.1021/bi200847n. [PMID] 21823612.
2011
Phosphorylation of Y372 is critical for Jak2 tyrosine kinase activation.
Cellular signalling. 23(11):1806-15 [DOI] 10.1016/j.cellsig.2011.06.015. [PMID] 21726629.
2011
The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow.
Neoplasia (New York, N.Y.). 13(11):1058-68 [PMID] 22131881.
2011
The stilbenoid tyrosine kinase inhibitor, G6, suppresses Jak2-V617F-mediated human pathological cell growth in vitro and in vivo.
The Journal of biological chemistry. 286(6):4280-91 [DOI] 10.1074/jbc.M110.200774. [PMID] 21127060.
2011
Vascular smooth muscle Jak2 deletion prevents angiotensin II-mediated neointima formation following injury in mice.
Journal of molecular and cellular cardiology. 50(6):1026-34 [DOI] 10.1016/j.yjmcc.2011.03.005. [PMID] 21420414.
2011
Vascular smooth muscle Jak2 mediates angiotensin II-induced hypertension via increased levels of reactive oxygen species.
Cardiovascular research. 91(1):171-9 [DOI] 10.1093/cvr/cvr059. [PMID] 21354995.
2010
Jak2 Plays a Critical and Non-Redundant Role in Hematopoiesis Throughout Pre- and Post-Natal Life.
Blood. 116
2010
Recent developments on JAK2 inhibitors: a patent review.
Expert opinion on therapeutic patents. 20(4):471-95 [DOI] 10.1517/13543771003639436. [PMID] 20205617.
2010
Structure-function correlation of G6, a novel small molecule inhibitor of Jak2: indispensability of the stilbenoid core.
The Journal of biological chemistry. 285(41):31399-407 [DOI] 10.1074/jbc.M110.168211. [PMID] 20667821.
2010
The constitutive activation of Jak2-V617F is mediated by a π stacking mechanism involving phenylalanines 595 and 617.
Biochemistry. 49(46):9972-84 [DOI] 10.1021/bi1014858. [PMID] 20958061.
2010
The recent medicinal chemistry development of Jak2 tyrosine kinase small molecule inhibitors.
Current medicinal chemistry. 17(36):4551-8 [PMID] 21062251.
2009
Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening.
Bioorganic & medicinal chemistry letters. 19(13):3598-601 [DOI] 10.1016/j.bmcl.2009.04.138. [PMID] 19447617.
2009
Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.
Current oncology reports. 11(2):117-24 [PMID] 19216843.
2008
Identification of tyrosine 972 as a novel site of Jak2 tyrosine kinase phosphorylation and its role in Jak2 activation.
Biochemistry. 47(32):8326-34 [DOI] 10.1021/bi800867d. [PMID] 18636744.
2008
Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth.
Molecular cancer therapeutics. 7(8):2308-18 [DOI] 10.1158/1535-7163.MCT-08-0279. [PMID] 18723478.
2007
Identification of tubulin as a substrate of Jak2 tyrosine kinase and its role in Jak2-dependent signaling.
Biochemistry. 46(24):7153-62 [PMID] 17530781.
2007
Jak2 tyrosine kinase and cancer: how good cells get HiJAKed.
Anti-cancer agents in medicinal chemistry. 7(6):643-50 [PMID] 18045059.
2007
The N-terminal SH2 domain of the tyrosine phosphatase, SHP-2, is essential for Jak2-dependent signaling via the angiotensin II type AT1 receptor.
Cellular signalling. 19(3):600-9 [PMID] 17027227.
2006
A functional Jak2 tyrosine kinase domain is essential for mouse development.
Experimental cell research. 312(15):2735-44 [PMID] 16887119.
2006
ANG II-induced cell proliferation is dually mediated by c-Src/Yes/Fyn-regulated ERK1/2 activation in the cytoplasm and PKCzeta-controlled ERK1/2 activity within the nucleus.
American journal of physiology. Cell physiology. 291(6):C1297-307 [PMID] 16723512.
2006
ERK1/2 regulates ANG II-dependent cell proliferation via cytoplasmic activation of RSK2 and nuclear activation of elk1.
American journal of physiology. Cell physiology. 291(6):C1308-17 [PMID] 16723511.
2006
Jak2 tyrosine kinase: a mediator of both housekeeping and ligand-dependent gene expression?
Cell biochemistry and biophysics. 44(2):213-22 [PMID] 16456223.
2005
Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophosphorylation [correction of autophophorylation].
Journal of medicinal chemistry. 48(7):2526-33 [PMID] 15801842.
2005
Jak2 tyrosine kinase prevents angiotensin II-mediated inositol 1,4,5 trisphosphate receptor degradation.
Vascular pharmacology. 43(5):336-45 [PMID] 16257270.
2004
A conformationally sensitive GHR [growth hormone (GH) receptor] antibody: impact on GH signaling and GHR proteolysis.
Molecular endocrinology (Baltimore, Md.). 18(12):2981-96 [PMID] 15345746.
2004
Jak2 tyrosine kinase mediates angiotensin II-dependent inactivation of ERK2 via induction of mitogen-activated protein kinase phosphatase 1.
The Journal of biological chemistry. 279(3):1956-67 [PMID] 14551204.
2004
Jak2 tyrosine kinase mediates oxidative stress-induced apoptosis in vascular smooth muscle cells.
The Journal of biological chemistry. 279(33):34547-52 [PMID] 15159394.
2004
Jak2 tyrosine kinase residues glutamic acid 1024 and arginine 1113 form a hydrogen bond interaction that is essential for Jak-STAT signal transduction.
Molecular and cellular biochemistry. 265(1-2):161-9 [PMID] 15543946.
2004
Jak2 tyrosine kinase: a true jak of all trades?
Cell biochemistry and biophysics. 41(2):207-32 [PMID] 15475610.
2004
Microarray analyses identify JAK2 tyrosine kinase as a key mediator of ligand-independent gene expression.
American journal of physiology. Cell physiology. 287(4):C981-91 [PMID] 15189810.
2004
Vaccinia virus-mediated high level expression and single step purification of recombinant Jak2 protein.
Protein expression and purification. 35(2):181-9 [PMID] 15135391.
2003
Janus kinase 2 determinants for growth hormone receptor association, surface assembly, and signaling.
Molecular endocrinology (Baltimore, Md.). 17(11):2211-27 [PMID] 12920237.
2003
The critical role of c-Src and the Shc/Grb2/ERK2 signaling pathway in angiotensin II-dependent VSMC proliferation.
Experimental cell research. 287(2):339-49 [PMID] 12837289.
2002
Mutation of glutamic acid residue 1046 abolishes Jak2 tyrosine kinase activity.
Molecular and cellular biochemistry. 241(1-2):87-94 [PMID] 12482029.
2001
Signal transduction mechanisms of the angiotensin II type AT(1)-receptor: looking beyond the heterotrimeric G protein paradigm.
Journal of the renin-angiotensin-aldosterone system : JRAAS. 2(1):4-10 [PMID] 11881054.
2001
Signal transduction pathways of angiotensin II in the kidney.
Contributions to nephrology. (135):16-33 [PMID] 11705281.
2001
The angiotensin II-dependent nuclear translocation of Stat1 is mediated by the Jak2 protein motif 231YRFRR.
The Journal of biological chemistry. 276(13):10556-63 [PMID] 11152457.
2000
Jak2 acts as both a STAT1 kinase and as a molecular bridge linking STAT1 to the angiotensin II AT1 receptor.
The Journal of biological chemistry. 275(20):15586-93 [PMID] 10748109.
2000
The role of Ca2+ mobilization and heterotrimeric G protein activation in mediating tyrosine phosphorylation signaling patterns in vascular smooth muscle cells.
Molecular and cellular biochemistry. 212(1-2):91-8 [PMID] 11108140.
1999
A catalytically active Jak2 is required for the angiotensin II-dependent activation of Fyn.
The Journal of biological chemistry. 274(46):33131-42 [PMID] 10551884.
1999
The angiotensin II-dependent association of Jak2 and c-Src requires the N-terminus of Jak2 and the SH2 domain of c-Src.
Circulation research. 84(11):1332-8 [PMID] 10364571.
1998
Angiotensin II signal transduction pathways.
Regulatory peptides. 78(1-3):19-29 [PMID] 9879743.
1998
Janus kinase 2 (Jak2) must be catalytically active to associate with the AT1 receptor in response to angiotensin II.
Biochemical and biophysical research communications. 249(3):672-7 [PMID] 9731195.
1998
New insights into the cellular signaling of seven transmembrane receptors: the role of tyrosine phosphorylation.
Laboratory investigation; a journal of technical methods and pathology. 78(1):3-7 [PMID] 9461117.
1998
Phosphorylation of p130Cas by angiotensin II is dependent on c-Src, intracellular Ca2+, and protein kinase C.
Circulation research. 82(12):1279-88 [PMID] 9648724.
1997
Cloning and partial characterization of the mouse glutamine:fructose-6-phosphate amidotransferase (GFAT) gene promoter.
Nucleic acids research. 25(7):1458-66 [PMID] 9060444.
1997
Dependence on the motif YIPP for the physical association of Jak2 kinase with the intracellular carboxyl tail of the angiotensin II AT1 receptor.
The Journal of biological chemistry. 272(37):23382-8 [PMID] 9287353.
1997
Role of intracellular calcium in the angiotensin II-mediated tyrosine phosphorylation and dephosphorylation of PLC-gamma 1.
Biochemical and biophysical research communications. 232(2):540-4 [PMID] 9125218.
1996
Glucose metabolism to glucosamine is necessary for glucose stimulation of transforming growth factor-alpha gene transcription.
The Journal of biological chemistry. 271(25):15237-43 [PMID] 8663078.
1994
Human immunodeficiency virus 1 Tat stimulates transcription of the transforming growth factor alpha gene in an epidermal growth factor-dependent manner.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research. 5(1):87-93 [PMID] 8123596.
1994
The murine glutamine:fructose-6-phosphate amidotransferase-encoding cDNA sequence.
Gene. 140(2):289-90 [PMID] 8144040.
1991
Triazolam fails to induce sleep in suprachiasmatic nucleus-lesioned rats.
Neuroscience letters. 125(2):125-8 [PMID] 1881590.

Grants

Sep 2016 ACTIVE
Vascular Smooth Muscle Lysyl Oxidase Mediated Increase in Vessel Stiffness and its Effect on Rho-Kinase Mechanosensors: A Novel Mechanism of Atherosclerosis in Chronic Kidney Disease?
Role: Other
Funding: NATL INST OF HLTH NHLBI
Jul 2015 – Jun 2018
Targeting Jak2 Kinase for the treatment of hypertension
Role: Principal Investigator
Funding: AMER HEART ASSOCIATION
Oct 2013 – Mar 2017
Pre-clinical Analysis of Novel Therapeutic Strategies
Role: Principal Investigator
Funding: CELL WORKS GROUP, INC.
Jul 2013 – Jun 2016
The role of vascular smooth muscle cell derived Jak2 tyrosine kinase in angiotensin II-mediated pathogenesis
Role: Principal Investigator
Funding: AMER HEART ASSOCIATION
Jul 2007 – Aug 2016
Clinical and Translational Science Institute
Role: Project Manager
Funding: UF RESEARCH FOU
Jul 2006 – Dec 2020
21st Century Research & Economic Development Investment Program (REDIP)
Role: Project Manager
Funding: STATE UNIV SYS OF FL BOARD OF GOVERNORS

Contact Details

Phones:
Business:
(352) 392-1816
Emails:
Business:
psayeski@ufl.edu
Addresses:
Business Mailing:
PO Box 100274
GAINESVILLE FL 32610
Business Street:
PO BOX 100274
GAINESVILLE FL 326100274